Possible Roles of Genetic Variations in Chemotherapy Related Cardiotoxicity in Pediatric Acute Lymphoblastic Leukemia and Osteosarcoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Jul 5

PMID 29970035

Citations 18

Authors

Judit C Sagi

Balint Egyed

Andrea Kelemen

Nora Kutszegi

Marta Hegyi

Andras Gezsi

Martina Ayaka Herlitschke

Andrea Rzepiel

Lili E Fodor

Gabor Ottoffy

Gabor T Kovacs

Daniel J Erdelyi

Csaba Szalai

Agnes F Semsei

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of acute lymphoblastic leukemia (ALL) and osteosarcoma (OSC) is very effective: the vast majority of patients recover and survive for decades. However, they still need to face serious adverse effects of chemotherapy. One of these is cardiotoxicity which may lead to progressive heart failure in the long term. Cardiotoxicity is contributed mainly to the use of anthracyclines and might have genetic risk factors. Our goal was to test the association between left ventricular function and genetic variations of candidate genes.

Methods: Echocardiography data from medical records of 622 pediatric ALL and 39 OSC patients were collected from the period 1989-2015. Fractional shortening (FS) and ejection fraction (EF) were determined, 70 single nucleotide polymorphisms (SNPs) in 26 genes were genotyped. Multivariate logistic regression and multi-adjusted general linear model were performed to investigate the influence of genetic polymorphisms on the left ventricular parameters. Bayesian network based Bayesian multilevel analysis of relevance (BN-BMLA) method was applied to test for the potential interaction of the studied cofactors and SNPs.

Results: Our results indicate that variations in ABCC2, CYP3A5, NQO1, SLC22A6 and SLC28A3 genes might influence the left ventricular parameters. CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)). SLC28A3 rs7853758 AA was 12% in ALL cases population, while only 1% among controls (p = 6.50E-03; OR = 11.56 (1.98-67.45)). Patients with ABCC2 rs3740066 GG genotype had lower FS during the acute phase of therapy and 5-10 years after treatment (p = 7.38E-03, p = 7.11E-04, respectively). NQO1 rs1043470 rare T allele was associated with lower left ventricular function in the acute phase and 5-10 years after the diagnosis (p = 4.28E-03 and 5.82E-03, respectively), and SLC22A6 gene rs6591722 AA genotype was associated with lower mean FS (p = 1.71E-03), 5-10 years after the diagnosis.

Conclusions: Genetic variants in transporters and metabolic enzymes might modulate the individual risk to cardiac toxicity after chemotherapy.

Citing Articles

Informing Hazard Identification and Risk Characterization of Environmental Chemicals by Combining Transcriptomic and Functional Data from Human-Induced Pluripotent Stem-Cell-Derived Cardiomyocytes.

Tsai H, Ford L, Burnett S, Dickey A, Wright F, Chiu W Chem Res Toxicol. 2024; 37(8):1428-1444.

PMID: 39046974 PMC: 11691792. DOI: 10.1021/acs.chemrestox.4c00193.

Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci.

Stafford L, Tang X, Brandt A, Ma J, Banchs J, Livingston J Pharmacogenomics J. 2024; 24(4):21.

PMID: 38951505 PMC: 11824427. DOI: 10.1038/s41397-024-00343-0.

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.

Xie H, Wen X, Wang Y, Huang X, Shu Q, Wang D Lupus Sci Med. 2023; 10(2).

PMID: 37993281 PMC: 10668244. DOI: 10.1136/lupus-2023-000997.

Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review.

Kouwenberg T, van Dalen E, Feijen E, Netea S, Bolier M, Slieker M BMC Cancer. 2023; 23(1):866.

PMID: 37710224 PMC: 10500898. DOI: 10.1186/s12885-023-11353-9.

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies.

Antoniadi K, Thomaidis N, Nihoyannopoulos P, Toutouzas K, Gikas E, Kelaidi C Diagnostics (Basel). 2023; 13(11).

PMID: 37296716 PMC: 10252297. DOI: 10.3390/diagnostics13111864.

References

Lal S, Wong Z, Sandanaraj E, Xiang X, Ang P, Lee E . Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008; 99(4):816-23. PMC: 11158672. DOI: 10.1111/j.1349-7006.2008.00744.x. View

Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L . MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009; 65(3):437-46. PMC: 2797421. DOI: 10.1007/s00280-009-1046-1. View

Armstrong G, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson M . Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014; 32(12):1218-27. PMC: 3986385. DOI: 10.1200/JCO.2013.51.1055. View

. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol. 2009; 145(3):376-88. PMC: 2812732. DOI: 10.1111/j.1365-2141.2009.07624.x. View

Visscher H, Amstutz U, Sistonen J, Ross C, Hayden M, Carleton B . Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011; 58(3):228-39. DOI: 10.1097/FJC.0b013e3182163b82. View

Huang Z, Wang J, Qian J, Li Y, Xu Z, Chen M . Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia. Mol Med Rep. 2017; 15(6):3493-3498. PMC: 5436286. DOI: 10.3892/mmr.2017.6470. View

Ito T, Fujio Y, Takahashi K, Azuma J . Degradation of NFAT5, a transcriptional regulator of osmotic stress-related genes, is a critical event for doxorubicin-induced cytotoxicity in cardiac myocytes. J Biol Chem. 2006; 282(2):1152-60. DOI: 10.1074/jbc.M609547200. View

Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M . Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics. 2012; 287(9):755-64. DOI: 10.1007/s00438-012-0715-7. View

Sundberg K, Doukkali E, Lampic C, Eriksson L, Arvidson J, Wettergren L . Long-term survivors of childhood cancer report quality of life and health status in parity with a comparison group. Pediatr Blood Cancer. 2010; 55(2):337-43. DOI: 10.1002/pbc.22492. View

10.

Hertz D, Caram M, Kidwell K, Thibert J, Gersch C, Seewald N . Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016; 17(3):231-40. PMC: 5558515. DOI: 10.2217/pgs.15.162. View

11.

Mordente A, Meucci E, Silvestrini A, Martorana G, Giardina B . New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009; 16(13):1656-72. DOI: 10.2174/092986709788186228. View

12.

Niemi M, Arnold K, Backman J, Pasanen M, Godtel-Armbrust U, Wojnowski L . Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006; 16(11):801-8. DOI: 10.1097/01.fpc.0000230422.50962.91. View

13.

Aminkeng F, Ross C, Rassekh S, Hwang S, Rieder M, Bhavsar A . Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016; 82(3):683-95. PMC: 5338111. DOI: 10.1111/bcp.13008. View

14.

Klein K, Thomas M, Winter S, Nussler A, Niemi M, Schwab M . PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012; 91(6):1044-52. DOI: 10.1038/clpt.2011.336. View

15.

Visscher H, Ross C, Rassekh S, Barhdadi A, Dube M, Al-Saloos H . Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2011; 30(13):1422-8. DOI: 10.1200/JCO.2010.34.3467. View

16.

Hattinger C, Biason P, Iacoboni E, Gagno S, Fanelli M, Tavanti E . Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget. 2016; 7(38):61970-61987. PMC: 5308704. DOI: 10.18632/oncotarget.11486. View

17.

Lal S, Mahajan A, Chen W, Chowbay B . Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab. 2010; 11(1):115-28. DOI: 10.2174/138920010791110890. View

18.

Leong S, Chaiyakunapruk N, Lee S . Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Sci Rep. 2017; 7(1):39. PMC: 5428315. DOI: 10.1038/s41598-017-00075-1. View

19.

Lipshultz S, Adams M . Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010; 28(8):1276-81. DOI: 10.1200/JCO.2009.26.5751. View

20.

Andersen V, Vogel L, Kopp T, Saebo M, Nonboe A, Hamfjord J . High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence. PLoS One. 2015; 10(3):e0119255. PMC: 4368545. DOI: 10.1371/journal.pone.0119255. View